vs
Side-by-side financial comparison of BioNTech SE (BNTX) and WEIBO Corp (WB). Click either name above to swap in a different company.
BioNTech SE is the larger business by last-quarter revenue ($1.5B vs $1.3B, roughly 1.2× WEIBO Corp). WEIBO Corp runs the higher net margin — 35.7% vs -1.9%, a 37.6% gap on every dollar of revenue.
BioNTech SE is a German multinational biotechnology company headquartered in Mainz that develops immunotherapies and vaccines, particularly for cancer and infectious diseases.
Weibo Corporation is a Chinese social network company known for the microblogging website Sina Weibo. It is based in Beijing, China.
BNTX vs WB — Head-to-Head
Income Statement — Q3 FY2025 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $1.5B | $1.3B |
| Net Profit | $-28.7M | $458.3M |
| Gross Margin | — | — |
| Operating Margin | -3.1% | 29.1% |
| Net Margin | -1.9% | 35.7% |
| Revenue YoY | — | — |
| Net Profit YoY | — | — |
| EPS (diluted) | — | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q3 25 | $1.5B | $1.3B | ||
| Q2 25 | $260.8M | $841.7M | ||
| Q1 25 | — | $396.9M | ||
| Q3 24 | $1.2B | $1.3B | ||
| Q2 24 | — | $833.4M | ||
| Q1 24 | — | $395.5M | ||
| Q3 23 | — | $1.3B | ||
| Q2 23 | — | $854.0M |
| Q3 25 | $-28.7M | $458.3M | ||
| Q2 25 | $-386.6M | $234.8M | ||
| Q1 25 | — | $108.1M | ||
| Q3 24 | $198.1M | $297.4M | ||
| Q2 24 | — | $164.6M | ||
| Q1 24 | — | $51.1M | ||
| Q3 23 | — | $268.8M | ||
| Q2 23 | — | $188.6M |
| Q3 25 | -3.1% | 29.1% | ||
| Q2 25 | -192.1% | 30.4% | ||
| Q1 25 | — | 27.8% | ||
| Q3 24 | 0.8% | 29.0% | ||
| Q2 24 | — | 28.2% | ||
| Q1 24 | — | 25.2% | ||
| Q3 23 | — | 27.3% | ||
| Q2 23 | — | 25.8% |
| Q3 25 | -1.9% | 35.7% | ||
| Q2 25 | -148.2% | 27.9% | ||
| Q1 25 | — | 27.2% | ||
| Q3 24 | 15.9% | 22.9% | ||
| Q2 24 | — | 19.8% | ||
| Q1 24 | — | 12.9% | ||
| Q3 23 | — | 20.7% | ||
| Q2 23 | — | 22.1% |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $1.1B |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | — | $3.9B |
| Total Assets | — | $6.9B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q3 25 | — | $1.1B | ||
| Q2 25 | — | $1.2B | ||
| Q1 25 | — | $1.2B | ||
| Q3 24 | — | — | ||
| Q2 24 | — | $1.9B | ||
| Q1 24 | — | $2.1B | ||
| Q3 23 | — | $2.8B | ||
| Q2 23 | — | $2.4B |
| Q3 25 | — | $3.9B | ||
| Q2 25 | — | $3.6B | ||
| Q1 25 | — | $3.5B | ||
| Q3 24 | — | — | ||
| Q2 24 | — | $3.4B | ||
| Q1 24 | — | $3.3B | ||
| Q3 23 | — | $3.2B | ||
| Q2 23 | — | $3.1B |
| Q3 25 | — | $6.9B | ||
| Q2 25 | — | $6.5B | ||
| Q1 25 | — | $6.7B | ||
| Q3 24 | — | — | ||
| Q2 24 | — | $7.1B | ||
| Q1 24 | — | $7.3B | ||
| Q3 23 | — | $6.7B | ||
| Q2 23 | — | $6.9B |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BNTX
Segment breakdown not available.
WB
| Income from operations | $373.2M | 29% |
| Shares used in computing diluted net income per share attributable to Weibos shareholders | $268.1M | 21% |
| Shares used in computing basic net income per share attributable to Weibos shareholders | $238.6M | 19% |
| Value-added services | $186.1M | 14% |
| Less: Income tax expenses | $113.2M | 9% |
| Investment related income, net | $45.0M | 4% |
| Product development | $16.7M | 1% |
| General and administrative | $10.6M | 1% |
| Sales and marketing | $7.1M | 1% |
| Accretion to redeemable non-controlling interests | $3.0M | 0% |
